Introduction
hematologic cancers, breast cancer
HEMATOLOGIC CANCER, BREAST CANCER
Effective approaches to overcome endocrine therapy (ET) resistance remain a major challenge in estrogen receptor (ER)–positive breast cancer management.We have previously demonstrated in luminal ERAlisertib’s safety and tolerability profile was well-defined in early phase trials in hematologic cancers.Based on our preclinical rationale, we conducted a phase 1 trial combining alisertib with fulvestrant in patients who previously received aromatase inhibitor (AI) therapy for ERConcurrent with alisertib development for MBC, the CDK 4/6is were established as optimal first or second-line therapies in combination with ET for ERGiven the phase 1 results and potential importance of AURKA in the setting of endocrine and CDK 4/6i resistance, we conducted an investigator-initiated, multicenter, randomized phase 2 clinical trial to evaluate alisertib alone or combined with fulvestrant in patients with endocrine-resistant, ERBB2